-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The umosatan hydrochlorophenidate tablet is a fixed-dose compound preparation developed by DAIICHISANKYO, which is mainly used to treat hypertension.
the drug was first marketed in the U.S. in 2003 and approved for import in 2010.
the drug as a Medicare Class B drug, the latest winning bid in China is 6.46 yuan per tablet.
2019, sales of Omishatan ester hydrochlorochlorophenicol tablets in domestic grade hospitals will be approximately RMB83.21 million.
Insight database shows that at present, in addition to the original research, only Huahai Pharmaceuticals in August the first imitation was approved, Beijing Fuyuan was approved as the second, no other enterprises have submitted a listing application.
only one company in the BE phase, for Zhejiang Nord Pharmaceuticals.
five other companies have been clinically approved, but most of them will not be clinical except for Luoxin, Shandong Province, in 2005/2006.
, the drug is still vacant in the market, approved generics companies are expected to occupy a larger market share.
from: Insight Database ()